Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases.
Zymenex is developing several human recombinant enzymes that can be used for therapy within specific disease areas. The products are expected to be able to help patients, who today have serious handicaps, reduced quality of life and a markedly reduced life expectancy. Enzyme replacement therapy is a well-known treatment method and there are a number of products on the market today that validates the company concept.
The company’s Research and Development focuses on Lysosomal Storage Diseases, which is a common name for human diseases, where the ability of the human body to break down specific molecules in the lysosomes in the cells is reduced or impaired. The diseases most often affect children, they are lethal and there is no therapy available today.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Roskildevej 12c, Hillerod,capital Region 3400,denmark
- Phone
- 45 48 25 00 54
- zx****@****nex.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- zymenex.com
- HQ
- Hillerod, Capital Region
Zymenex Questions
Zymenex's helpline number is 45 48 25 00 54
Zymenex's website is zymenex.com
Zymenex's LinkedIn profile is https://dk.linkedin.com/company/zymenex
Zymenex has
4 employees.
View email and phone details for 4
employees at Zymenex.
Zymenex's industry is
Biotechnology Research
Zymenex's top competitors are
Stragen Nordic A/s,
Resother Pharma,
Pharmakon - Courses For Life Science,
Bavarian Nordic,
Cytovac Ab,
Monta Biosciences,
Genomic Expression Inc,
Mc2 Therapeutics,
Biogen,
Gubra.
Zymenex's support email address is zxmail@zymenex.com
Zymenex's categories are Biotechnology Research
Zymenex's founding year is 1998
